Cargando…
Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer
Background: Despite remarkable success of immunotherapies with checkpoint blockade antibodies targeting programmed cell death protein 1 (PD-1), the majority of patients with non-small-cell lung cancer (NSCLC) have yet to receive durable benefits. We used the metabolomic profiling of early on-treatme...
Autores principales: | Nie, Xiaoqun, Xia, Liliang, Gao, Fang, Liu, Lixia, Yang, Yi, Chen, Yingying, Duan, Huangqi, Yao, Yaxian, Chen, Zhiwei, Lu, Shun, Wang, Ying, Yang, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176105/ https://www.ncbi.nlm.nih.gov/pubmed/34095230 http://dx.doi.org/10.3389/fmolb.2021.678753 |
Ejemplares similares
-
Early‐like differentiation status of systemic PD‐1(+)
CD8
(+) T cells predicts PD‐1 blockade outcome in non‐small cell lung cancer
por: Khanniche, Asma, et al.
Publicado: (2022) -
Predictive Value of Preoperative Profiling of Serum Metabolites for Emergence Agitation After General Anesthesia in Adult Patients
por: Wang, Qian, et al.
Publicado: (2021) -
Clinical application of serum biomarkers for detecting and monitoring of chronic plaque psoriasis
por: Cruz, Criselda Jean G., et al.
Publicado: (2023) -
Exosomal miR-590-5p in Serum as a Biomarker for the Diagnosis and Prognosis of Gastric Cancer
por: Zheng, Guo-Dian, et al.
Publicado: (2021) -
A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry
por: Yang, Jiayue, et al.
Publicado: (2021)